Product Description
Cerlapirdine is a Wyeth/Pfizer selective 5-HT6 receptor antagonist for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7356)
Mechanisms of Action: 5-HT6 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Alzheimer Disease
Phase 1: Alzheimer Disease|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-101240 | P2 |
Completed |
Alzheimer Disease |
2011-11-30 |
|
| 3193A1-2005 | P2 |
Terminated |
Alzheimer Disease |
2011-05-01 |
|
| 3193A1-1103 | P1 |
Completed |
Healthy Volunteers |
2011-03-01 |
|
| 3193A1-1109 | P1 |
Completed |
Alzheimer Disease |
2009-12-01 |